[1]刘璐璐,邵国良,庞佩佩.磁共振弥散加权和动态增强成像评价晚期肝癌TACE术疗效研究进展 [J].介入放射学杂志,2017,(08):756-759.
　LIU Lulu,SHAO Guoliang,PANG Peipei.Application of diffusion- weighted and dynamic contrast- enhanced MRI in evaluating the curative effect of TACE for advanced hepatocellular carcinoma： recent progress in research[J].journal interventional radiology,2017,(08):756-759.
点击复制

磁共振弥散加权和动态增强成像评价晚期肝癌TACE术疗效研究进展


()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2017年08期
页码:
756-759
栏目:
综述
出版日期:
2017-08-25

文章信息/Info

Title:
Application of diffusion- weighted and dynamic contrast- enhanced MRI in evaluating the curative effect of TACE for advanced hepatocellular carcinoma： recent progress in research
作者:
刘璐璐;  邵国良;  庞佩佩
Author(s):
LIU Lulu;  SHAO Guoliang;  PANG Peipei
Zhejiang University of Traditional Chinese Medicine， Hangzhou， Zhejiang Province 310053， China
关键词:
【关键词】 肝细胞癌;  经导管动脉化疗栓塞术;  磁共振弥散加权成像;  磁共振动态对比增强
文献标志码:
A
摘要:
【摘要】 TACE是治疗晚期肝细胞癌较为成熟有效的方法，术后快速准确、创伤最小地评价其疗效，确定下一步治疗方案尤为重要。目前临床上评价TACE术后疗效主要取决于CT和MR形态成像，但事实上肿瘤功能特性改变早于形态变化。近年来，弥散加权成像（DWI）、多b值DWI、动态对比增强（DCE）成像等MR功能成像越来越多地用于定量评价肿瘤组织内水分子扩散和血流微循环灌注，且在评价肿瘤疗效上取得了一定进展。该文就上述功能成像方法研究进展及在TACE疗效评价中的应用现状作一综述。

参考文献/References:

［1］ Song DS， Bae SH. Changes of guidelines diagnosing hepatocellular carcinoma during the last ten- year period［J］. Clin Mol Hepatol， 2012， 18： 258- 267.
［2］ Tsurusaki M， Murakami T. Surgical and locoregional therapy of HCC： TACE［J］. Liver Cancer， 2015， 4： 165- 175.
［3］ Raoul JL， Park JW， Kang YK， et al. Using modified RECIST and alpha- fetoprotein levels to assess treatment benefit in hepato- cellular carcinoma［J］. Liver Cancer， 2014， 3： 439- 450.
［4］ Maniam S， Szklaruk J. Magnetic resonance imaging： review of imaging techniques and overview of liver imaging［J］. World J Radiol， 2010， 2： 309- 322.
［5］ Battal B， Kocaoglu M， Akgun V， et al. Diffusion- weighted imaging in the characterization of focal liver lesions： efficacy of visual assessment［J］. Comput Assist Tomogr， 2011， 35： 326- 331.
［6］ Hardie AD， Kizziah MK， Boulter DJ， et al. Diagnostic accuracy of diffusion- weighted MRI for identifying hepatocellular carcinoma with liverexplant correlation［J］. J Med Imaging Radiat Oncol， 2011， 55： 362- 367.
［7］ Yuan Z， Li WT， Ye XD， et al. Utility of diffusion- weighted imaging to assess hepatocellular carcinoma viability following transarterial chemoembolization［J］. Oncol Lett， 2014， 8： 831- 836.
［8］ Drevelegas K， Nikiforaki K， Constantinides M， et al. Apparent diffusion coefficient quantification in determining the histological diagnosis of malignant liver lesions［J］. J Cancer， 2016， 7： 730- 735.
［9］ Che S， Zhao X， Ou Y， et al. Role of the intravoxel incoherent motion diffusion weighted imaging in the pre- treatment prediction and early response monitoring to neoadjuvant chemotherapy in locally advanced breast cancer［J］. Medicine （Baltimore）， 2016， 95： e2420.
［10］ Sun YS， Cui Y， Tang L， et al. Early evaluation of cancer response by a new functional biomarker： apparent diffusion coefficient［J］. Am J Roentgenol， 2011， 197： W23- W29.
［11］ 罗 敏， 高源统， 彭文献， 等． 扩散加权序列动态评估原发性肝癌疗效的应用价值［J］． 放射学实践， 2011， 26： 55- 58．
［12］ 李振武， 张 伟， 孙立军， 等． 磁共振扩散加权成像在肝癌化疗栓塞术后随访中的价值［J］． 介入放射学杂志， 2010， 19： 610- 612．
［13］ Kokabi N， Camacho JC， Xing M， et al. Immediate post- doxorubicin drug- eluting beads chemoembolization MR apparent diffusion coefficient quantification predicts response in unresectable hepato- cellular carcinoma： a pilot study［J］. J Magn Reson Imaging， 2015， 42： 981- 989.
［14］ Park YS， Lee CH， Kim JH， et al. Using intravoxel incoherent motion （IVIM） MR imaging to predict lipiodol uptake in patients with hepatocellular carcinoma following transcatheter arterial chemoembolization： a preliminary result［J］. Magn Reson Imaging， 2014， 32： 638- 646.
［15］ Sobhani F， Xu C， Murano E， et al. Hypo- vascular liver metastases treated with transarterial chemoembolization： assessment of early response by volumetric contrast- enhanced and diffusion- weighted magnetic resonance imaging［J］. Transl Oncol， 2016， 9： 287- 294.
［16］ Gluskin JS， Chegai F， Monti S， et al. Hepatocellular carcinoma and diffusion- weighted MRI： detection and evaluation of treatment response［J］. J Cancer， 2016， 7： 1565- 1570.
［17］ Jajamovich GH， Huang W， Besa C， et al. DCE- MRI of hepatocellular carcinoma： perfusion quantification with Tofts model versus shutter- speed model： initial experience［J］. MAGMA， 2016， 29： 49- 58.
［18］ Chen BB， Hsu CY， Yu CW， et al. Dynamic contrast- enhanced MR imaging of advanced hepatocellular carcinoma：comparison with the liver parenchyma and correlation with the survival of patients receiving systemic therapy［J］. Radiology， 2016， 281： 454- 464.
［19］ Kim HY， Choi JY， Kim CW， et al. Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid- enhanced magnetic resonance imaging predicts the histological grade of hepatocellular carcinoma only in patients with Child- Pugh class A cirrhosis［J］. Liver Transpl， 2012， 18： 850- 857.
［20］ Bolog N， Andreisek G， Oancea I， et al. CT and MR imaging of hepatocellular carcinoma［J］. J Gastrointestin Liver Dis， 2011， 20： 181- 189.
［21］ Kim KA， Park MS， Ji HJ， et al. Diffusion and perfusion MRI prediction of progression- free survival in patients with hepatocellular carcinoma treated with concurrent chemoradio- therapy［J］. J Magn Reson Imaging， 2014， 39： 286- 292.
［22］ Taouli B， Johnson RS， Hajdu CH， et al. Hepatocellular carcinoma： perfusion quantification with dynamic contrast- enhanced MRI［J］. AJR Am J Roentgenol， 2013， 201： 795- 800.
［23］ Heo YJ， Park JE， Kim HS， et al. Prognostic relevance of gemistocytic grade Ⅱastrocytoma： gemistocytic component and MR imaging features compared to non- gemistocytic gradeⅡ astrocytoma［J］. Eur Radiol， 2017， 27: 3022- 3032.
［24］ 周智鹏， 黄仲奎.动态增强 MRI 定量参数对肝癌诊断和随访的研究进展［J］. 临床放射学杂志， 2014， 33： 794- 796.
［25］ Jarnagin WR， Schwartz LH， Gultekin DH， et al. Regional chemotherapy for unresectable primary liver cancer： results of a phase Ⅱ clinical trial and assessment of DCE- MRI as a biomarker of survival［J］. Ann Oncol， 2009， 20： 1589- 1595.
［26］ 潘 奇， 任 静， 侯炜寰， 等． 3.0 T MR动态增强扫描定量分析在肝癌TACE术后疗效评估中的应用［J］． 临床放射学杂志， 2015， 34： 919- 923．
［27］ Chen G， Ma DQ， He W， et al. Computed tomography perfusion in evaluating the therapeutic effect of transarterial chemoembo- lization for hepatocellular carcinoma［J］. World J Gastroenterol， 2008， 14： 5738- 5743.

相似文献/References:

[1]姚雪松,李 槐.不可手术切除的肝细胞癌的疗效评价标准——改良ＲＥＣＩＳＴ标准更可靠[J].介入放射学杂志,2012,(03):177.
　. Ｔｈｅｒａｐｅｕｔｉｃ ｅｖａｌｕａｔｉｏｎ ｃｒｉｔｅｒｉｏｎ ｏｆ ｉｎｏｐｅｒａｂｌｅ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ： ｍｏｄｉｆｉｅｄ ＲＥＣＩＳＴ ａｓ ａ ｍｏｒｅ ｒｅｌｉａｂｌｅ ｓｔａｎｄａｒｄ[J].journal interventional radiology,2012,(08):177.
[2]梁茂全,苏洪英. 肝癌化疗栓塞前后甲胎蛋白变化模式的临床意义[J].介入放射学杂志,2012,(04):333.
　.Ｔｈｅ ｔｒａｎｓｆｏｒｍａｔｉｏｎ ｐａｔｔｅｒｎ ｏｆ ｓｅｒｕｍ аｆｅｔｏｐｒｏｔｅｉｎ ａｆｔｅｒ ｔｒａｎｓｃａｔｈｅｔｅｒ ａｒｔｅｒｉａｌ ｃｈｅｍｏｅｍｂｏｌｉｚａｔｉｏｎ ｉｎ ｐａｔｉｅｎｔｓ ｗｉｔｈ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａ： ｉｔｓ ｃｌｉｎｉｃａｌ ｓｉｇｎｉｆｉｃａｎｃｅ [J].journal interventional radiology,2012,(08):333.
[3]孙 磊,施海彬,刘 圣,等.肝细胞癌肝动脉门静脉分流形成的相关因素分析[J].介入放射学杂志,2012,(03):206.
　,,et al.Ｔｈｅ ｆａｃｔｏｒｓ ｒｅｌａｔｅｄ ｔｏ ｔｈｅ ｆｏｒｍａｔｉｏｎ ｏｆ ａｒｔｅｒｉｏｐｏｒｔａｌ ｓｈｕｎｔｉｎｇ ｉｎ ｐａｔｉｅｎｔｓ ｗｉｔｈ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ [J].journal interventional radiology,2012,(08):206.
[4]王惠文,刘瑞宝,刘　　　岩,等.原发性肝癌ＴＡＣＥ后ＦＡＫ、ＮＦκＢｐ６５表达及意义[J].介入放射学杂志,2011,(08):621.
　WANG Hui-wen,LIU Rui-bao,LIU Yan,et al.The expression and significance of FAK and NF-κBp65 in hepatocellular carcinoma after transcatheter arterial chemoembolization[J].journal interventional radiology,2011,(08):621.
[5]沈海洋,刘瑞宝,刘 岩,等. 肝右叶前、后段原发性肝癌TACE后VEGF及CD34的表达水平 ；[J].介入放射学杂志,2012,(06):469.
　SHEN Hai- yang,LIU Rui- bao,LIU Yan,et al. The expression levels of vascular endothelial growth factor and CD34 in residual cancerous tissues of primary hepatocellular carcinoma located at anterior and posterior segments of right lobe liver after TACE[J].journal interventional radiology,2012,(08):469.
[6]李晓峰,钱国军,张 磊,等. 微波高功率条件下消融原发性肝癌的初步研究[J].介入放射学杂志,2011,(12):974.
　LI Xiao-feng,QIAN Guo-jun,ZHANG Lei,et al.Microwave ablation with high output power for the treatment of hepatocellular carcinoma: a preliminary study[J].journal interventional radiology,2011,(08):974.
[7]赵 艳,韩国宏,白 苇,等. 药物缓释微球肝动脉化疗栓塞治疗肝癌研究进展[J].介入放射学杂志,2012,(01):78.
　ZHAO Yan,HAN Guo-hong,BAI Wei,et al.Transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma: its research progress[J].journal interventional radiology,2012,(08):78.
[8]彭辽河,胡晓燕,李 杰,等. 18F-FDG PET/CT显像在肝细胞癌TACE术后残留或复发病灶检出中的应用价值[J].介入放射学杂志,2012,(08):636.
　PENG Liao- he,HU Xiao- yan,LI Jie,et al. Clinical application of 18F- FDG PET/CT imaging in detecting residual lesions or recurrence foci of hepatocellular carcinoma after TACE treatment[J].journal interventional radiology,2012,(08):636.
[9]陆小华,朱小庆,茅国新.肝细胞癌相关单核苷酸多态性的研究进展[J].介入放射学杂志,2013,(06):520.
　LU Xiao? hua,ZHU Xiao? qing,MAO Guo? xin.. Hepatocellular carcinoma?蛳 related single nucleotide polymorphisms： recent advances in research[J].journal interventional radiology,2013,(08):520.
[10]姚雪松,闫 东,曾辉英,等.TACE联合索拉非尼治疗不能手术切除肝细胞癌介入治疗间隔时间的分析[J].介入放射学杂志,2014,(09):769.
　YAO Xue song,YAN Dong,ZENG Hui ying,et al.TACE combined with sorafenib for inoperable hepatocellular carcinoma： analysis of treatment interval[J].journal interventional radiology,2014,(08):769.
[11]王以浪,王亚非,张 亮,等. 肝细胞癌患者TACE术前后血清miR- 21表达变化及临床意义[J].介入放射学杂志,2014,(05):406.
　WANG Yi- lang,WANG Ya- fei,ZHANG Liang,et al. The changes of serum miR- 21 expression level in patients with HCC before and after TACE and its clinical significance[J].journal interventional radiology,2014,(08):406.
[12]尹芝兰,肖恩华.原发性肝癌行TACE术后对乙型肝炎病毒影响[J].介入放射学杂志,2014,(12):1114.
　YIN Zhi lan,XIAO En hua..The influence of TACE for primary hepatocellular carcinoma on hepatitis B virus[J].journal interventional radiology,2014,(08):1114.
[13]中国医师协会介入医师分会.中国肝细胞癌经动脉化疗栓塞治疗（TACE）临床实践指南[J].介入放射学杂志,2018,27(12):1117.
　Chinese College of Interventionalists,Chinese Medical Doctor Association.Chinese Clinical Practice Guidelines for transarterial chemoembolization of hepatocellular carcinoma[J].journal interventional radiology,2018,27(08):1117.
[14]张 申,张 磊,仲斌演,等.“TACE抵抗/失败”——需要全面认识[J].介入放射学杂志,2020,29(08):743.
　ZHANG Shen,ZHANG Lei,ZHONG Binyan,et al.Comprehensive understanding of the concept and connotation of “TACE- failure/refractoriness”[J].journal interventional radiology,2020,29(08):743.
[15]刘 嵘,程永德,王小林,等.中国肝细胞癌TACE治疗的历史、现状和展望 ——纪念我国介入放射学奠基人林贵教授[J].介入放射学杂志,2022,31(08):743.
　LIU Rong,CHENG Yongde,WANG Xiaolin,et al.The history, status and future of transarterial chemoembolization of hepatocellular carcinoma in China: in memory of Professor Gui Lin, the founder of interventional radiology in China[J].journal interventional radiology,2022,31(08):743.
[16]夏子聪,赵 辉.改善经导管动脉化疗栓塞术疗效的临床及基础研究进展[J].介入放射学杂志,2023,32(07):705.
　XIA Zicong,ZHAO Hui..Advances in clinical and fundamental researches for improving the efficacy of transcatheter arterial chemoembolization[J].journal interventional radiology,2023,32(08):705.
[17]陆一峰,王 祁,何忠明.构建基于控制营养状况评分的列线图预测肝细胞癌TACE治疗患者预后[J].介入放射学杂志,2023,32(12):1190.
　LU Yifeng,WANG Qi,HE Zhongming..Construction of a nomogram based on controlling nutritional status score for predicting the prognosis of hepatocellular carcinoma patients after receiving TACE[J].journal interventional radiology,2023,32(08):1190.
[18]管清龙,陈海波,刘成龙,等.体素内不相干运动-弥散加权成像评价不同栓塞材料经动脉化疗栓塞治疗肝细胞癌效果及预后[J].介入放射学杂志,2024,33(02):140.
　GUAN Qinglong,CHNE Haibo,LIU Chenglong,et al.The application of IVIM-DWI in evaluating the efficacy and prognosis of TACE using different embolization materials for hepatocellular carcinoma[J].journal interventional radiology,2024,33(08):140.
[19]隰子涵,杨永波,邵国良.MRI和临床危险因素对中晚期肝细胞癌首次D-TACE近期疗效预测价值分析[J].介入放射学杂志,2024,33(04):376.
　XI Zihan,YANG Yongbo,SHAO Guoliang..The value of MRI and clinical risk factors in predicting the short-term efficacy of initial D-TACE in patients with intermediate and advanced stage hepatocellular carcinoma[J].journal interventional radiology,2024,33(08):376.

备注/Memo

备注/Memo:
（收稿日期：２０１6-1０-27）
（本文编辑：边 佶）
更新日期/Last Update: 2017-08-11